---
canonical_name: Thylakoids
alternate_names: Spinach-Derived Thylakoids, Thylakoid Membranes, Green-Plant Membranes, Chloroplast Membranes, Thylakoid-Rich Spinach Extract
canonical_topic: Thylakoids for Health & Longevity
short_topic_lc: thylakoids
creation_date: 2026-0627-0227
creator_ai_fullname: Opus 4.8
---

# Thylakoids for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/27/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Spinach-Derived Thylakoids, Thylakoid Membranes, Green-Plant Membranes, Chloroplast Membranes, Thylakoid-Rich Spinach Extract


## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->

Thylakoids are the flat, stacked green membranes inside plant leaves, where they carry out the light-capturing step of photosynthesis. When extracted and concentrated from green leaves such as spinach, they are taken before meals as a dietary supplement. The interest lies not in their plant function but in an observation made as they pass through the human gut: they appear to slow fat digestion and prompt the body to release its own natural fullness signals, which may curb hunger and the pull toward sweet and fatty foods.

This idea grew out of work at a Swedish university, where researchers noticed that a green-membrane fraction reduced appetite in animals and then tested it in people carrying extra weight. Early short studies reported less hunger and fewer cravings, and one longer study reported greater weight loss. Because excess weight is closely tied to long-term health, a low-cost food-derived option naturally draws attention from those focused on healthy aging.

This review examines what the human evidence shows about thylakoids for appetite, weight, and related measures, how they are thought to work, how they are used, and what risks and open questions remain.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-quality, accessible overviews that discuss thylakoids and their appetite and weight effects in depth, prioritizing recognized experts in health and longevity.

<!-- Real-time searches were performed across the web and directly on the platforms of the priority experts (Rhonda Patrick/foundmyfitness.com, Peter Attia/peterattiamd.com, Andrew Huberman/hubermanlab.com, Chris Kresser/chriskresser.com, Life Extension/lifeextension.com) for "thylakoid" and "spinach extract appetite". Two priority experts had directly relevant, dedicated content: Rhonda Patrick's FoundMyFitness and Life Extension Magazine (a dedicated feature on the spinach/thylakoid appetite extract). No dedicated, substantial coverage of thylakoids was found on the Attia, Huberman, or Kresser platforms. The list is completed with high-quality expert and academic overviews that discuss the intervention by name in depth. No more than one item per source is included. -->

* [A spinach extract containing green leaf membranes called thylakoids decreased hedonic hunger up to 95% and increased weight loss by 43%](https://www.foundmyfitness.com/stories/ehqhaz) - Rhonda Patrick

 A concise expert summary from a leading longevity communicator highlighting the headline appetite and weight findings, useful as an accessible entry point to the thylakoid satiety hypothesis.

* [Spinach Extract: An Effective Weight Loss Supplement?](https://www.healthline.com/nutrition/spinach-extract-and-weight-loss) - Atli Arnarson

 A clear, evidence-referenced narrative overview of how thylakoid-rich spinach extract is proposed to work and what the human trials have and have not shown, written by a nutrition scientist.

* [Spinach extract decreases cravings, aids weight loss](https://www.sciencedaily.com/releases/2014/09/140902114928.htm) - Lund University

 A plain-language report on the Lund University three-month weight-loss study, valuable for understanding the origin and framing of the central long-term human finding.

* [Thylakoids from spinach enhance weight loss, new study shows](https://nutraceuticalbusinessreview.com/thylakoids-from-spinach-enhance-weight-loss-new-study-shows-101391) - Nutraceutical Business Review

 An industry-side overview of the same long-term study, useful for seeing how the finding was positioned for the supplement market and the commercial interests involved.

* [Stop Unhealthy Food Cravings](https://www.lifeextension.com/magazine/2019/2/stop-unhealthy-food-cravings) - Michael Downey

 A Life Extension Magazine feature focused on the spinach-derived thylakoid extract and its effect on cravings and hunger, framing the appetite findings explicitly within a healthy-aging and longevity context for a proactive audience.

<!-- Note to reader: Two priority experts (Rhonda Patrick and Life Extension Magazine) had directly relevant, dedicated content on thylakoids; Attia, Huberman, and Kresser did not. The remaining items are the strongest non-priority expert and academic-adjacent overviews found that discuss the intervention by name in depth. -->


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "thylakoid". A dedicated primary page titled "Thylakoid" exists at /page/Thylakoid. -->

[Thylakoid](https://grokipedia.com/page/Thylakoid) - Grokipedia

 The Grokipedia entry covers the biology and structure of thylakoid membranes in detail; it is centered on photosynthesis rather than dietary supplementation, but it is the site's primary, dedicated page for the term.


## Examine

<!-- examine.com was searched directly using the browser tool for "thylakoid". A dedicated supplement page titled "Thylakoids" exists at /supplements/thylakoids/. -->

[Thylakoids](https://examine.com/supplements/thylakoids/)

 Examine's evidence-based supplement page summarizes the research on thylakoids for appetite, weight, and metabolic outcomes, providing an independent, study-graded assessment of the claims.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "thylakoid". No dedicated product review or article for thylakoids exists; only a general "appetite suppressant supplements" CL Answer mentions related ingredients. -->

No dedicated ConsumerLab article or product review for thylakoids exists. ConsumerLab's testing focuses on widely marketed supplement categories, and thylakoid-specific products are not currently covered.


## Systematic Reviews

This section summarizes the systematic-review-level evidence identified for thylakoid supplementation through a real-time PubMed search.

* [Thylakoid supplementation and hunger and fullness perception: a systematic review and dose-response meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/38518202/) - Nikrad et al., 2025

 This dose-response meta-analysis of five randomized controlled trials found that combining thylakoids with meals significantly reduced hunger and increased fullness on visual analog scales, with effects strongest at shorter intervention durations; the authors stress that the trial base is small and inconsistent and that further trials are needed.

* [Effects of thylakoid intake on appetite and weight loss: a systematic review](https://pubmed.ncbi.nlm.nih.gov/32550209/) - Amirinejad et al., 2020

 This earlier qualitative systematic review of eight human clinical trials found consistent support for thylakoids reducing hunger via raised postprandial cholecystokinin and leptin and lowered ghrelin, while noting that the effects on body weight and anthropometric measures were inconsistent across studies; it predates and complements the 2025 meta-analysis.

<!-- A real-time PubMed search for "thylakoid AND (systematic review OR meta-analysis)" returned two thylakoid-specific qualifying reviews: the 2025 dose-response meta-analysis (PMID 38518202) and the 2020 qualitative systematic review (PMID 32550209). Other hits (e.g., PMID 41849936, 40289507) concern plant photosynthesis, not dietary supplementation, and were excluded as off-topic. -->


## Mechanism of Action

The proposed mechanism centers on the slowing of fat digestion in the small intestine and the resulting amplification of the body's own satiety signaling.

* **Lipase inhibition and delayed fat digestion:** Thylakoid membranes bind to and partially inhibit pancreatic lipase (the enzyme that breaks dietary fat into absorbable units) and interact with bile salts and the fat-water interface. This slows—rather than blocks—fat breakdown, so fat reaches the lower small intestine instead of being fully absorbed in the upper segment.

* **Stimulation of satiety hormones:** When undigested fat reaches the lower intestine, it triggers the so-called "ileal brake." This prompts release of satiety hormones including cholecystokinin (CCK, a gut hormone that signals fullness and slows stomach emptying) and glucagon-like peptide-1 (GLP-1, a gut hormone that promotes fullness and helps regulate blood sugar), while reducing the hunger hormone ghrelin. Human trials have measured elevated CCK and GLP-1 after thylakoid-supplemented meals.

* **Reduced hedonic eating:** By raising satiety hormones linked to the brain's reward pathways, thylakoids are proposed to reduce "hedonic hunger"—cravings for palatable sweet and fatty foods—beyond simple caloric fullness. Trials report reduced wanting and liking for sweets after supplementation.

* **Competing interpretation:** An alternative reading is that much of the measured benefit reflects short-term visual-analog-scale changes that do not consistently translate into reduced food intake or durable weight loss. Several acute trials showed reduced hunger ratings without a significant reduction in measured energy intake, leaving open whether the hormonal signal meaningfully changes behavior over time.

Thylakoids are a complex plant-membrane preparation rather than a single defined molecule, so they have no characterized pharmacological half-life, receptor selectivity, or hepatic metabolism profile in the conventional drug sense; their action is local to the gut lumen.


## Historical Context & Evolution

* **Original biological role:** Thylakoids are not a designed therapeutic. They are the internal membrane system of chloroplasts, where chlorophyll-protein complexes capture light energy to drive photosynthesis in plants, algae, and cyanobacteria. Their dietary study is entirely incidental to this function.

* **Origin of the appetite hypothesis:** Research at Lund University in Sweden, led by the group of Charlotte Erlanson-Albertsson, observed in the 2000s that a green-leaf membrane fraction could inhibit pancreatic lipase and reduce food intake and body-weight gain in rodents. This led to the hypothesis that the same fraction could amplify satiety signaling in humans.

* **Move into human study:** From roughly 2013 onward, the Lund group and collaborators ran a series of short-term and three-month human trials in overweight women, reporting reduced hunger, elevated CCK and GLP-1, reduced cravings, and—in one longer study—greater weight loss. Later independent trials, largely from Iranian research groups, extended testing to obese women with polycystic ovary syndrome and to men undergoing exercise training.

* **Current standing:** The findings are described by the original researchers as the actual measured outcomes—real reductions in hunger ratings and real hormonal shifts—rather than as debunked or established. The 2025 meta-analysis confirmed a statistically significant short-term satiety signal while emphasizing that the evidence base is small, heterogeneous, and not yet sufficient to establish durable clinical weight effects. The picture remains open: supportive short-term signals coexist with unresolved questions about long-term efficacy.


## Expected Benefits

A dedicated search of clinical trials, the 2025 meta-analysis, and expert sources was performed to assemble the complete benefit profile below. Benefits are framed for risk-aware adults considering thylakoids as part of a deliberate weight- and metabolic-management effort.


### Medium 🟩 🟩

#### Reduced Hunger and Increased Fullness

When taken with a meal, thylakoids consistently reduce subjective hunger and increase fullness on visual analog scales, the most replicated finding across the literature. The proposed mechanism is delayed fat digestion and amplified release of the satiety hormones cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1). The 2025 dose-response meta-analysis of five randomized controlled trials found significant effects in both directions, strongest within shorter interventions; the main limitation is reliance on self-rated scales that do not always track measured food intake.

**Magnitude:** Pooled weighted mean difference of about −2.4 mm for hunger and +4.6 mm for fullness on 0–100 mm visual analog scales; single trials report up to ~20% lower hunger and ~14% greater satiety acutely.


#### Reduced Cravings for Palatable Food

Thylakoid supplementation reduces the "wanting" and "liking" of sweet, salty, and fat-rich snacks, an effect distinct from general fullness and attributed to satiety hormones acting on brain reward pathways. Evidence comes from randomized crossover and parallel trials in overweight women, with effects most pronounced in those scoring higher for emotional eating. The relevance for this audience is the potential to blunt the craving-driven overeating that undermines deliberate dietary efforts, though trials are small and short.

**Magnitude:** Roughly 30–38% reductions in cravings for sweets and snacks in single trials; reductions in the urge for chocolate and sweets sustained over three months in one longer study.


### Low 🟩

#### Greater Weight and Fat Loss

In a single three-month randomized trial, overweight women taking 5 g of green-plant membranes daily before breakfast lost more weight than placebo while following a three-meal pattern. Smaller controlled trials in obese women with polycystic ovary syndrome combined with calorie restriction reported greater reductions in weight, waist circumference, and fat mass than calorie restriction alone. The evidence is limited by small samples, mostly single research groups, and inconsistent ad-libitum-intake findings, so durable weight effects remain unproven.

**Magnitude:** About 5.0 kg loss versus 3.5 kg with placebo over 12 weeks (~43% greater) in the Lund study; ~7.0 kg versus ~3.2 kg over 12 weeks with calorie restriction in the polycystic ovary syndrome trial.


#### Improved Insulin Sensitivity and Glycemic Measures

Several trials, particularly those combining thylakoids with calorie restriction or exercise in metabolically impaired populations, report reductions in fasting insulin and insulin-resistance indices and prevention of post-meal blood-sugar dips. The proposed basis is slowed nutrient absorption and incretin (gut hormone) effects on glucose handling. Findings are most evident when thylakoids are added to an active diet or training program rather than used alone.

**Magnitude:** Significant reductions in fasting insulin (e.g., ~5 µU/mL greater fall than placebo) and HOMA-IR (a calculated index of insulin resistance) in 12-week trials; acute prevention of postprandial hypoglycemia in meal-test studies.


#### Improved Blood Lipids

A subset of trials reports reductions in total and LDL (low-density lipoprotein, the "bad" cholesterol) and triglycerides with thylakoid supplementation, plausibly linked to reduced fat absorption and improved metabolic profile during weight loss. Effects are inconsistent across studies and often confounded by co-administered calorie restriction or exercise, so the independent contribution of thylakoids is uncertain.

**Magnitude:** Significant reductions in total and LDL cholesterol versus placebo in the 12-week Lund study; lipid improvements in exercise-combined trials with effect sizes around 0.7–0.9.


### Speculative 🟨

#### Favorable Shifts in Adipokines and Inflammatory Markers

Exercise-combined trials in men with obesity report changes in fat-tissue signaling proteins (adipokines such as adiponectin, leptin, and omentin) and a reduction in a marker of gut-barrier leakage, with a parallel rise in brain-derived neurotrophic factor in one trial. These outcomes are mechanistically interesting for longevity but rest on small single-group studies where thylakoids were combined with training or diet, so any independent effect is anecdotal at this stage.


#### Longevity-Relevant Metabolic Benefit

Because excess adiposity and insulin resistance are strongly tied to age-related disease, a tool that genuinely reduces craving-driven overeating could in principle support long-term metabolic health. This extrapolation is mechanistic and indirect; no thylakoid trial has measured aging, disease incidence, or survival endpoints.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** No genetic variant has been studied as a modifier of thylakoid benefit. Because the action is local to the gut lumen rather than dependent on a drug-metabolizing enzyme, candidate variants would more plausibly involve fat-handling, incretin (gut hormone), or appetite-signaling pathways (e.g., CCK or GLP-1 receptor variants) than the hepatic CYP enzymes relevant to absorbed drugs; none of these has been tested, so any genetic modification of benefit is currently unknown.

* **Sex differences:** Several trials enrolled only women, while a crossover trial found that men showed a trend toward reduced energy intake whereas women did not, and craving effects appeared gender-specific. The benefit profile may differ meaningfully between sexes, and female-only data dominate the appetite literature.

* **Baseline eating behavior:** Individuals scoring higher on emotional or hedonic eating measures showed larger reductions in cravings for palatable food, suggesting the craving benefit is concentrated in those whose overeating is reward-driven rather than purely homeostatic.

* **Pre-existing conditions:** In obese women with polycystic ovary syndrome (a hormonal and metabolic disorder), thylakoids added to calorie restriction produced clearer anthropometric and insulin benefits, indicating that metabolically impaired groups may respond more strongly than metabolically healthy individuals.

* **Baseline appetite level:** Meta-analysis subgroup findings suggest hunger reduction was greater in participants starting with lower baseline hunger and fullness gains greater in those starting with higher baseline fullness, so starting state appears to modify the measured effect.

* **Co-intervention context:** Benefits are most consistent when thylakoids accompany an active calorie-restricted diet, a structured three-meal pattern, or an exercise program, and least consistent when used as a standalone supplement without behavioral support.

* **Age:** Trials enrolled mostly adults from young adulthood through about 65 years; no data address whether response differs at the older end of this range, so age-related modification is unstudied.


## Potential Risks & Side Effects

A dedicated search of trial safety reports, the meta-analysis, and supplement reference sources was performed. Thylakoids are a food-derived preparation with a generally benign reported safety profile, but the data are limited to small, short trials.


### Low 🟥

#### Mild Gastrointestinal Effects

Because thylakoids slow but do not block fat digestion, fat still reaches the lower intestine, which can theoretically cause mild bloating, altered bowel habits, or transient digestive discomfort. Unlike the fat-blocking drug orlistat, thylakoids are not associated with oily stools or fecal urgency in the published trials, and gastrointestinal complaints were not prominent. The evidence basis is trial tolerability reporting in a few hundred participants.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Reduced Fat-Soluble Nutrient Absorption

Any agent that delays or reduces fat digestion could, in principle, reduce absorption of fat-soluble vitamins (A, D, E, K) and carotenoids if used heavily and chronically. No thylakoid trial has measured fat-soluble vitamin status, so this concern is mechanistic and theoretical, drawn from the known behavior of lipase-modulating agents.


#### Allergy or Plant-Protein Sensitivity

Thylakoid extracts contain plant proteins and chlorophyll-protein complexes derived from spinach or other leaves, so allergic or hypersensitivity reactions are biologically possible in sensitized individuals. No such cases are documented in the trial literature; the concern rests on the general principle that any concentrated plant-protein preparation can be allergenic.


#### Unknown Long-Term Safety

The longest controlled human exposure is roughly three months, and total trial experience is a few hundred participants. Long-term safety, including effects of sustained lipase modulation and any impact on gut hormone signaling over years, is unstudied. This is an absence of evidence rather than evidence of harm.


## Risk-Modifying Factors

* **Genetic polymorphisms:** No genetic variant has been studied as a modifier of thylakoid risk or tolerability. Because thylakoids are not systemically absorbed and are not cleared by hepatic drug-metabolizing enzymes, common pharmacogenetic variants (e.g., CYP enzyme polymorphisms) are not an expected source of differential risk; any genetically driven difference in side-effect susceptibility would more plausibly relate to plant-protein allergy predisposition or fat-handling variants, none of which has been examined.

* **Use of fat-soluble vitamin supplements or low-fat diets:** Individuals with marginal vitamin A, D, E, or K status, or those combining thylakoids with very low-fat diets or other fat-absorption-modifying agents, could theoretically face a greater risk of reduced fat-soluble nutrient absorption.

* **Known plant or spinach allergy:** Those with established spinach or leaf-vegetable allergy or broad plant-protein sensitivity may face elevated allergy risk from concentrated leaf-membrane extracts.

* **Pre-existing gastrointestinal conditions:** People with conditions involving fat malabsorption, bile-acid disorders, or pancreatic insufficiency could in principle experience altered tolerability, though no trial has examined these groups.

* **Pregnancy and lactation:** No trials enrolled pregnant or breastfeeding women, so safety in these groups is undefined and they represent an untested population rather than a documented risk.

* **Sex and baseline metabolism:** Because efficacy and intake effects differed by sex, the risk-benefit balance (e.g., taking a supplement with limited benefit) may also differ; men and women may not derive equivalent value, which modifies the practical risk of ineffective use.

* **Age:** Trials enrolled mostly adults up to about 65–70 years, so risk in older adults at the upper end of the target range is essentially unstudied. Older individuals are more prone to marginal fat-soluble vitamin status and to polypharmacy, which could in principle amplify the theoretical malabsorption and interaction risks, but no trial has examined age as a modifier of thylakoid safety.


## Key Interactions & Contraindications

* **Prescription weight-loss and lipase-related drugs:** Combining thylakoids with the lipase inhibitor orlistat (a fat-absorption-blocking medication) is theoretically additive on fat malabsorption and could increase gastrointestinal side effects and fat-soluble vitamin depletion. **Severity:** caution. **Consequence:** additive malabsorption, possible vitamin deficiency. **Mitigation:** avoid stacking; separate fat-soluble vitamin intake if both are used.

* **Glucose-lowering medications:** Because thylakoids can blunt post-meal glucose excursions and prevent post-meal lows, people taking insulin or sulfonylureas (insulin-stimulating diabetes drugs) could theoretically experience altered glycemic responses. **Severity:** monitor. **Consequence:** changes in blood-sugar control. **Mitigation:** monitor glucose when starting.

* **Incretin-based therapies:** Thylakoids raise endogenous GLP-1; their combination with GLP-1 receptor agonists (injectable appetite-and-glucose drugs such as semaglutide) has not been studied, and any additive appetite or gastrointestinal effect is unknown. **Severity:** caution. **Consequence:** unknown additive effect. **Mitigation:** clinical supervision if combined.

* **Over-the-counter medications:** No specific over-the-counter drug interactions are documented. Theoretically, agents taken with meals whose absorption depends on dietary fat could be modestly affected by delayed fat digestion. **Severity:** caution. **Consequence:** possible minor absorption changes. **Mitigation:** separate timing if concerned.

* **Supplements – additive satiety/fat agents:** Other fiber-based or fat-binding satiety supplements (e.g., glucomannan, chitosan) could be additive on satiety and on fat-soluble nutrient reduction. **Severity:** caution. **Consequence:** additive malabsorption risk. **Mitigation:** avoid redundant stacking; ensure fat-soluble vitamin intake.

* **Supplements – fat-soluble vitamins and carotenoids:** Fat-soluble vitamin (A, D, E, K) and carotenoid supplements may be modestly less absorbed if taken in the same meal as thylakoids. **Severity:** monitor. **Consequence:** reduced absorption. **Mitigation:** take fat-soluble vitamins in a meal not co-administered with thylakoids.

* **Populations who should avoid or use caution:** Pregnant or breastfeeding women (no safety data), individuals with known spinach or leaf-vegetable allergy, those with significant fat-malabsorption or pancreatic insufficiency, and anyone with marginal fat-soluble vitamin status should approach with caution or avoid, given the absence of trial data in these groups.


## Risk Mitigation Strategies

* **Separate fat-soluble vitamins from dosing:** To mitigate the theoretical reduction in vitamin A, D, E, and K absorption, take any fat-soluble vitamin or carotenoid supplement at a meal that does not contain the thylakoid dose, rather than concurrently.

* **Start with a single pre-meal dose:** To limit gastrointestinal discomfort and gauge tolerability, protocols typically use one 5 g dose before a single meal (commonly breakfast) rather than at every meal, with digestive response observed over the first one to two weeks before any increase.

* **Avoid stacking with fat-blocking agents:** To prevent additive fat malabsorption and possible vitamin depletion, do not combine thylakoids with orlistat or other fat-binding supplements such as chitosan.

* **Monitor blood sugar if on glucose-lowering drugs:** To mitigate altered glycemic responses, more frequent glucose monitoring when starting thylakoids is advisable for individuals using insulin or sulfonylureas, with attention to changes in post-meal readings.

* **Screen for allergy before use:** To prevent allergic reactions, concentrated leaf-membrane extracts are best avoided by those with known spinach or leaf-vegetable allergy; for individuals with broad plant sensitivities, a cautious start with discontinuation at any sign of reaction is the prudent approach.

* **Pair with structured meal patterns:** To capture the most consistent benefit and avoid reliance on the supplement alone, thylakoids are best paired with a defined three-meal pattern or calorie-restricted plan, which is the context in which trials saw the clearest effects.


## Therapeutic Protocol

* **Standard dose and timing:** The most studied protocol, used by the original Lund University researchers, is 5 g of thylakoid-rich extract taken once daily before breakfast, mixed into a drink, yogurt, or other food. Acute studies used a single 5 g dose before a meal.

* **Best time of day:** Pre-breakfast dosing dominates the literature, on the rationale that establishing satiety early reduces compensatory eating and cravings later in the day; the meta-analysis is consistent with meal-paired dosing being the effective pattern.

* **Single versus split dosing:** Trials used a single daily pre-meal dose rather than split dosing; the satiety signal is meal-triggered, so pairing the dose with the meal whose intake one most wants to influence is the standard approach. Some dose-response data suggest 5 g and ~7.4 g per day both produce effects.

* **Half-life consideration:** Thylakoids are a non-absorbed gut-acting plant-membrane preparation with no defined systemic half-life; their effect is tied to the presence of fat in the meal they accompany, not to a circulating drug level, so dosing is anchored to meals rather than to a dosing interval.

* **Competing approaches:** A conventional framing treats thylakoids as one optional adjunct within standard diet-and-exercise weight management, while an integrative framing positions them as a craving-control tool for hedonic eaters; neither is established as superior, and most trials embed thylakoids within calorie restriction or exercise rather than as a standalone therapy.

* **Genetic factors:** No pharmacogenetic variants (e.g., affecting lipase or incretin signaling) have been studied as predictors of thylakoid response; gene-based dose selection is not currently possible.

* **Sex-based differences:** Because a crossover trial found energy-intake reductions trending in men but not women, and most efficacy data come from women, the optimal protocol may differ by sex; this remains unresolved.

* **Age considerations:** Protocols were tested in adults up to roughly 65 years; no age-specific dose adjustments are defined, and response in older adults at the upper end of the range is unstudied.

* **Baseline biomarkers and conditions:** Greater anthropometric and insulin benefit appeared in metabolically impaired groups (obesity, polycystic ovary syndrome), suggesting baseline insulin resistance and adiposity may predict stronger response, though this is observational across trials rather than a validated selection criterion.


## Discontinuation & Cycling

* **Lifelong versus short-term:** Thylakoids are positioned as a short-to-medium-term aid for appetite and weight management rather than a lifelong intervention; the longest controlled use is about three months, and no data support indefinite use.

* **Withdrawal effects:** No withdrawal syndrome is described. Because the effect is a meal-by-meal satiety signal with no systemic accumulation, stopping is expected simply to remove the appetite-modifying signal at subsequent meals.

* **Tapering:** No tapering protocol is needed or described; the supplement can be stopped abruptly without any documented rebound beyond the return of baseline appetite.

* **Cycling:** No cycling regimen has been studied. Meta-analysis subgroup findings that effects were strongest at shorter durations raise the untested possibility that benefit may wane with continuous long-term use, but whether cycling would preserve responsiveness is unknown.


## Sourcing and Quality

* **Source material and formulation:** Thylakoid supplements are concentrated leaf-membrane extracts, most often from spinach (*Spinacia oleracea*), supplied as powders or sachets; concentration and membrane integrity vary by manufacturing process, which can affect potency.

* **What to look for:** Prefer products that specify the source plant, the thylakoid or green-membrane content per serving (the studied dose is 5 g), and ideally reference the standardized extract used in published trials; third-party testing for purity, heavy metals, and microbial contamination is desirable given that leafy-green concentrates can accumulate contaminants.

* **Reputable supply:** The most-studied material derives from Swedish research-linked preparations (e.g., the Greenleaf/Appethyl-type extract used in Lund trials); commercial products marketed as "spinach extract for appetite" vary widely, and matching the trial-grade material is not always possible.

* **Quality caveat:** Because thylakoids are a complex membrane preparation rather than a defined molecule, batch-to-batch and brand-to-brand variability in active-membrane content is a genuine concern, and the absence of a standardized assay on most consumer labels makes verification difficult.


## Practical Considerations

* **Time to effect:** Appetite and craving effects are acute, appearing within a single meal in test-meal studies; weight effects in the one longer trial accrued over the full 12 weeks, so the expected pattern is rapid satiety changes but slow, modest weight change at best.

* **Common pitfalls:** Expecting standalone weight loss without dietary change, taking the dose apart from a fat-containing meal (which weakens the satiety trigger), using under-dosed or poorly characterized "spinach extract" products, and over-relying on short-term hunger ratings as proof of long-term benefit are the main mistakes.

* **Regulatory status:** Thylakoid extracts are sold as dietary supplements, not approved drugs; they are not regulated for weight-loss efficacy, and marketing claims often outrun the evidence.

* **Cost and accessibility:** Thylakoid-specific products are a niche category, less widely available than mainstream supplements and sometimes more expensive per serving; this is a practical access consideration rather than a prohibitive cost.


## Interaction with Foundational Habits

* **Sleep:** The interaction is indirect and largely unstudied. By reducing evening cravings and late-day overeating, better appetite control could modestly support sleep and circadian eating patterns, but no trial measured sleep outcomes; there is no evidence thylakoids disrupt sleep.

* **Nutrition:** The interaction is direct and potentiating. Thylakoids require a fat-containing meal to trigger their satiety mechanism, work best paired with structured three-meal patterns or calorie restriction, and could modestly reduce absorption of fat-soluble vitamins—so timing fat-soluble nutrients apart from the dose and ensuring adequate dietary fat at the dosing meal are practical considerations.

* **Exercise:** The interaction is direct and potentiating in the available data. Several trials combined thylakoids with high-intensity functional training in men with obesity and reported amplified improvements in adipokines, insulin resistance, and lipids versus training alone, suggesting thylakoids may complement rather than blunt exercise adaptations; there is no evidence of impaired training response.

* **Stress management:** The interaction is indirect. By blunting reward-driven cravings, thylakoids may help counter stress- or emotion-triggered eating, an effect strongest in high-emotional-eaters; no trial measured cortisol or stress physiology directly, so any effect on the stress response itself is unestablished.


## Monitoring Protocol & Defining Success

Baseline assessment before starting helps define realistic targets and identify the metabolic measures most likely to shift; ongoing monitoring focuses on weight, appetite, and metabolic markers over the typical 12-week use window.

Baseline testing should be performed before starting, capturing body weight, waist circumference, and the fasting metabolic and lipid markers below, alongside a subjective baseline of hunger and craving patterns. Ongoing monitoring is reasonable at roughly 6 weeks and 12 weeks, then every 3–6 months if use continues, with body weight and waist circumference checked most frequently and blood markers re-checked at 12 weeks.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --------- | ------------------------ | --------------- | ------------- |
| Body weight / waist circumference | Stable or trending down toward a healthy waist (<94 cm men, <80 cm women) | Primary practical outcome | Measure fasting, same time of day; weekly trend more useful than single readings |
| Fasting glucose | 70–90 mg/dL | Tracks glycemic effect | Fasting 8–12 h; pair with insulin for HOMA-IR |
| Fasting insulin | 2–6 µU/mL | Detects insulin-sensitivity change | Fasting; combine with glucose to compute insulin resistance (HOMA-IR). Conventional labs often flag insulin only above ~25 µU/mL, so this functional target is tighter |
| HbA1c | <5.4% | Longer-term glucose control | HbA1c (glycated hemoglobin, a measure of average blood sugar over recent months). No fasting needed; reflects ~3-month average, well-suited to 12-week window |
| Total cholesterol | <180 mg/dL | Tracks lipid response | Fasting 9–12 h preferred; interpret with full panel |
| LDL cholesterol | <100 mg/dL (lower if higher risk) | Lipid marker reported to fall in trials | Fasting; best paired with triglycerides and HDL (high-density lipoprotein, the "good" cholesterol). Conventional labs accept LDL up to ~130 mg/dL, so this functional target is tighter, reflecting optimization rather than a disease threshold |
| Triglycerides | <80 mg/dL | Fat-metabolism marker | Fasting 12 h; sensitive to recent diet and alcohol |

Qualitative markers complement the labs and are often the most immediately noticeable:

* **Hunger and fullness:** Reduced between-meal hunger and earlier fullness at meals.

* **Cravings:** Fewer or weaker urges for sweet, salty, and fatty snacks, especially in the late day.

* **Eating behavior:** Less compensatory or emotional overeating after the dosing meal.

* **Energy and steadiness:** Steadier post-meal energy without sharp blood-sugar dips.


## Emerging Research

* **Registered-trial landscape:** As of this review, ClinicalTrials.gov lists only two thylakoid trials, both completed and both small: a glucose-handling study ([NCT02702245](https://clinicaltrials.gov/study/NCT02702245); Region Skåne; n=21; completed) and an earlier metabolic-health study ([NCT02687295](https://clinicaltrials.gov/study/NCT02687295); n=20; completed). No ongoing or recruiting thylakoid trial is currently registered, so the active research signal comes from recently published trials rather than from registered pipeline studies — itself a marker of how thin the formal trial base remains.

* **Completed mechanistic trial – glucose handling:** A small completed trial examined two doses of thylakoids on an oral glucose tolerance test and insulin sensitivity in healthy volunteers (the registry condition field labels the cohort "glucose intolerance," but eligibility enrolled metabolically healthy adults), reflecting continued interest in the metabolic, not just appetite, effects. [NCT02702245](https://clinicaltrials.gov/study/NCT02702245) (Region Skåne; n=21; completed).

* **Exercise-combined adipokine research:** Recent randomized trials continue to test thylakoids combined with high-intensity functional training in men with obesity, reporting shifts in adipokines and insulin resistance; this line could strengthen the case for thylakoids as an exercise adjunct. See [Saeidi et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37576981/) and a 2026 extension, [Razi et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41683333/).

* **Gut-brain axis and polycystic ovary syndrome (PCOS):** Trials in women with polycystic ovary syndrome are probing gut-barrier, neurotrophic, and oxidative-stress endpoints, testing whether thylakoid benefits extend beyond appetite into the gut-brain axis; results have been mixed, with some endpoints unchanged. See [Nikrad et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37968684/).

* **Future direction – durable weight efficacy:** The clearest gap, and the area most likely to change current understanding in either direction, is whether short-term satiety signals translate into durable weight and body-composition change in adequately powered, longer, multi-center trials that measure actual food intake, not only ratings. The 2025 meta-analysis ([Nikrad et al., 2025](https://pubmed.ncbi.nlm.nih.gov/38518202/)) explicitly calls for such trials, which could either substantiate or undercut the weight-loss claim.

* **Future direction – independent replication:** Much of the strongest data comes from a small number of research groups; independent replication outside the originating Swedish and Iranian centers would weigh heavily on whether the effects generalize.


## Conclusion

Thylakoids are concentrated green-leaf membranes, usually from spinach, taken before meals in the hope of curbing hunger and cravings. The most consistent finding is that, paired with a meal, they reduce self-rated hunger and increase fullness, and they appear to dampen cravings for sweet and fatty foods—effects linked to slowed fat digestion and the release of the body's own fullness signals. Beyond appetite, a single longer study and a few small trials in people with extra weight or hormonal-metabolic conditions point toward modest extra weight loss, better blood-sugar handling, and improved cholesterol, especially when thylakoids accompany a calorie-controlled diet or exercise rather than being used alone.

The evidence remains early and uneven. Most studies are small, short, focused on women, and run by a handful of research groups, and the strongest appetite signals come from self-rated scales that do not always translate into eating less or lasting weight change. Safety in the short term looks favorable, with no major reported harms, though long-term use is untested and a few theoretical concerns—such as reduced uptake of fat-soluble vitamins—remain unexamined. Some of the research carries commercial interest from the extract's developers. Thylakoids are best understood as a promising but unproven appetite-support option whose durable benefits are not yet established.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**


<section id="iterations" markdown="1"></section>